Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
56. |
ECCT/21/09/04 | Recombinant COVID-19 Vaccine A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells) for the prevention of COVID-19 in adults aged 18 years and older |
Principal Investigator(s) 1. Sylvester Kimaiyo Site(s) in Kenya 1. KAVI-Institute of Clinical Research (Nairobi City county) 2. Moi Teaching and Referral Hospital (Uasin Gishu county) 3. Kenya Medical Research Institute, Kilifi (Kilifi county) |
View |
57. |
ECCT/15/12/02 | The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial A Multi Centre, Open label, Randomized Clinical Trial, Comparing HIV incidence and Contraceptive Benefits in Women using Depot Medroxyprogesterone Acetate, Levernogestrel (LNG) implant and Copper Intrauterine Devices (IUD). Short Title : The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial |
Principal Investigator(s) 1. Prof Elizabeth Anne Bukusi Site(s) in Kenya KEMRI-RCTP Study center , Lumumba |
View |
58. |
ECCT/21/02/01 | PTSD 102 TONIX A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants with PTSD Taken Daily at Bedtime (Protocol No. TNX-CY-P308). |
Principal Investigator(s) 1. Prof. Lukoye Atwoli Site(s) in Kenya 1. Moi Teaching and Referral Hospital/Moi University (Uasin Gishu county) 2. KEMRI Nairobi (Nairobi City county) 3. Aga Khan University Hospital (Nairobi City county) |
View |
59. |
ECCT/19/04/02 | NADIA \"Nucleosides And Darunavir/Dolutegravir In Africa\" A randomised controlled trial of darunavir versus dolutegravir and tenofovir versus zidovudine in second-line antiretroviral therapy regimens for the public health approach in sub-Saharan Africa |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya Moi University Clinical Research Centre |
View |
60. |
ECCT/20/06/02 | EMPACTA Covid19 Study A RANDOMIZED, DOUBLE-BLIND, Placebo-Controlled, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB IN HOSPITALIZED PATIENTS WITH COVID‑19 PNEUMONIA |
Principal Investigator(s) 1. Reena Shah Site(s) in Kenya AgaKhan University Hospital Nairobi |
View |